<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119439</url>
  </required_header>
  <id_info>
    <org_study_id>1050</org_study_id>
    <nct_id>NCT05119439</nct_id>
  </id_info>
  <brief_title>Mifepristone and Two Doses of Misoprostol for Abortion at 11&amp;12 Weeks</brief_title>
  <official_title>An Outpatient Medical Abortion Regimen With Mifepristone and Two Doses of Misoprostol at 71-77 and 78-84 Days of Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the efficacy, side effect profile and acceptability of a medical&#xD;
      abortion regimen with mifepristone and two doses of 800 mcg misoprostol buccally at 71-77 and&#xD;
      78-84 days of gestation to further expand the evidence base for the most effective regimens&#xD;
      in the late first trimester of pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy as determined by the proportion of successful abortions without aspiration or D&amp;E for any reason</measure>
    <time_frame>7-36 days after initial visit</time_frame>
    <description>Proportion of women who achieve complete abortion with medication only and without aspiration or D&amp;E</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who report each individual side effect</measure>
    <time_frame>7-14 days after initial visit</time_frame>
    <description>Side effects include diarrhea, nausea, vomiting, fever, chills</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of complications experienced by participants that warrant visits to emergency room and/or hospitalization</measure>
    <time_frame>7-14 days after initial visit</time_frame>
    <description>Complications could include abnormal bleeding, severe pain, retained tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who determine method acceptable</measure>
    <time_frame>7-36 days after initial visit</time_frame>
    <description>Overall acceptability, time to complete abortion, bleeding, side effects, pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">171</enrollment>
  <condition>Medical Abortion</condition>
  <arm_group>
    <arm_group_label>71-77 days of gestational age</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Pregnant people whose pregnancies are estimated to have a gestational age of 71-77 days. (Participants in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>78-84 days of gestational age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant people whose pregnancies are estimated to have a gestational age of 78-84 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone + 2 doses of misoprostol 800 mcg</intervention_name>
    <description>Will use a mifepristone-misoprostol regimen of: 200 mg mifepristone followed in 24-48 hours by a first dose of 800 µg misoprostol buccally and then in another 4 hours by a second dose of 800 µg misoprostol buccally. For buccal administration of misoprostol, participants will place 2 misoprostol tablets in each cheek and hold them for 20-30 minutes, after which they will swallow any remnants.</description>
    <arm_group_label>78-84 days of gestational age</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Seeking medical abortion services at one of the enrolling clinics&#xD;
&#xD;
          -  Have an intrauterine pregnancy 71-77 days of gestation or 78-84 days&#xD;
&#xD;
          -  Meet standard eligibility criteria for medical abortion&#xD;
&#xD;
          -  Be able to return to clinic for in-person follow up&#xD;
&#xD;
          -  Speak/read/write English or Spanish&#xD;
&#xD;
          -  Have access to a mobile phone with texting capability&#xD;
&#xD;
          -  Be in general good health&#xD;
&#xD;
          -  Be willing and able to sign consent forms&#xD;
&#xD;
          -  Agree to comply with the study procedures and follow up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not eligible to consent on their own to being in a study (Age criteria may vary by&#xD;
             site according to state law.)&#xD;
&#xD;
          -  With known allergies or other contraindications to mifepristone or misoprostol&#xD;
&#xD;
          -  Desiring to start depot medroxyprogesterone acetate (DMPA) as contraception method&#xD;
             immediately because of potential interaction with mifepristone. Those who wish to wait&#xD;
             until abortion completion to start DMPA will be eligible for enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilana G Dzuba, MHS</last_name>
    <phone>+1.212.448.1230</phone>
    <email>idzuba@gynuity.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atlanta Women's Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Mark-Christopher Adams, DNP, MHA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Hawaii</name>
      <address>
        <city>Hilo</city>
        <state>Hawaii</state>
        <zip>96720</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bliss Kaneshiro, MD, MPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96822</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bliss Kaneshiro, MD, MPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood North Central States</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christy Boraas, MD, MPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philadelphia Women's Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Curtiss Hannum, MSN, APN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHOICES Memphis Center for Reproductive Health</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nikia Grayson, DNP, MPH, CNM, FNP</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood Great Northwest, Hawai'i, Alaska, Indiana, Kentucky</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Erin Berry, MD, MPH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood Great Northwest, Hawai'i, Alaska, Indiana, Kentucky</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Erin Berry, MD,MPH</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mifepristone</keyword>
  <keyword>misoprostol</keyword>
  <keyword>first trimester</keyword>
  <keyword>abortion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

